The FDA approved Vistogard (uridine triacetate) as an emergency treatment for patient having severe toxic reactions or receiving an unintentional overdose of either fluorouracil or capecitabine. The treatment is a breakthrough for these patients and can be a life saver and/or permit earlier reintroduction of necessary chemotherapy.
While it cannot be used to prevent the toxic effects (because it will reduce the effectiveness of these drugs), it provides the healthcare provider with a new option to treat the symptoms as soon as they become evident.
The drug (which received Fast Track designation and a priority review) is also subject to Orphan Drug Exclusivity as it has received orphan drug designations. The FDA press release can be viewed here.
